BOONTON, N.J., Jan. 12, 2021 /PRNewswire/ -- Enteris
BioPharma, Inc., a biotechnology company developing innovative drug
products built around its proprietary delivery technologies and a
wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH),
announced that the company will host a webinar, titled "Strategies
for Entering Phase 1 Clinical Development with Limited API
Quantities." The event is scheduled for Tuesday, January 19, 2021 at 1:30 p.m., ET, and will be co-hosted by
Thomas Daggs, MBA, Enteris' Senior
Director Product Development and Quality Control, and Angelo Consalvo, Enteris' Director
Manufacturing.
During the webinar, Mr. Daggs and Mr. Consalvo will discuss
their expertise in developing CMC approaches for advancing
pharmaceutical companies into Phase 1 clinical development, while
managing limited access to active pharmaceutical ingredients, also
known as API.
"The earliest stages of drug development can be the most
daunting, particularly for emerging pharmaceutical and
biotechnology companies, which often must contend with limited
resources, including access to API," said Rajiv Khosla, Ph.D., Chief Executive Officer of
Enteris. "At Enteris, we have encountered this situation with our
development partners, and our manufacturing team has been able to
devise strategies for developing CMC approaches that can be applied
to a wide range of Phase 1 trial demands. This webinar, which
is the second in a series of virtual events that Enteris is
hosting, is designed to share our knowledge and expertise with
those who desire novel strategies for initiating clinical programs
with limited API quantities."
Details of the webinar are as follows:
Title: Strategies for Entering Phase 1 Clinical
Development with Limited API Quantities
Date: Tuesday, January 19, 2020
Time: 1:30 p.m. ET
Webinar Link:
https://zoom.us/webinar/register/WN_RWaEgsjSSHCVUcBwVv2Wpg
About Thomas Daggs,
MBA
As Senior Director Product Development and Quality
Control at Enteris, Mr. Daggs is responsible for the Analytical and
Quality Control groups as well as CMC project management.
With more than 15 years of pharma, biotech and diagnostics
experience, Mr. Daggs possesses broad knowledge of all aspects of
pharmaceutical development with technical strengths in analytical
methodology/controls.
About Angelo Consalvo
As Director of Manufacturing at Enteris, Mr. Consalvo is
responsible for cGMP manufacturing and pre-formulation
characterization studies. Mr. Consavlo has more than 34 years
of biopharma experience in process development and manufacturing.
Throughout his career, he has led the successful development and
transfer of numerous commercial manufacturing processes and built
an expertise in working with small molecule and peptide/protein
APIs, both recombinant and synthetic.
About Enteris BioPharma
Enteris BioPharma, Inc. is a
wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH)
offering innovative formulation solutions utilizing its proprietary
drug delivery technologies, Peptelligence® and
ProPerma™. The technologies have been the subject of numerous
feasibility studies and active development programs, several of
which are in late-stage clinical development. Additionally, Enteris
BioPharma is advancing an internal product pipeline of oral tablet
reformulations of drug products that address significant treatment
opportunities for which there is no oral delivery option. Enteris
BioPharma's most advanced internal product candidate,
Ovarest® (oral leuprolide tablet), is an oral peptide
being developed for the treatment of endocrine disorders.
TobrateTM (oral tobramycin tablet) is also being
developed by Enteris BioPharma for the treatment of uncomplicated
urinary tract infection (uUTI). A third internal compound,
octreotide, is currently in preclinical development. For more
information on Enteris BioPharma and its proprietary oral delivery
technology, please visit http://www.EnterisBioPharma.com.
View original
content:http://www.prnewswire.com/news-releases/enteris-biopharma-to-host-webinar-on-strategies-for-initiating-phase-1-clinical-development-with-limited-api-301206170.html
SOURCE Enteris BioPharma, Inc.